TB kills more people than any other infectious disease and is the leading killer of people living with HIV; about one in three deaths among people with HIV are due to TB.
The Global Fund provides 69% of all international financing for tuberculosis (10% of total available resources) and has disbursed US$6.6 billion for TB programs and US$2.1 for TB/ HIV programs as of June 2019. As the leading international funder of TB programs, the Global Fund is a critical partner in achieving the new targets set at the UN High-Level Meeting.
See the results of these initiative and others in the fight against tuberculosis worldwide in the Global Fund’s Results Report 2019 .
GFAN Speaker Timur Abdullaev shares his insights as an HIV+ person who received lifesaving tuberculosis treatment from a Global Fund program with participants of the RESULTS International Conference. He is confident that we can...
Publisher: Friends of the Global Fight Against AIDS, Tuberculosis and Malaria
The world has made remarkable progress over the past two decades to address AIDS, tuberculosis and malaria, and increased investment can help ensure disease resurgence does not undo these gains. Stepped-up funding for the Global Fund and U.S. bilateral programs is our best defense against future disease resurgence.
The path forward is clear: to end AIDS, tuberculosis and malaria, we must scale up prevention and treatment, strengthen surveillance systems and invest in innovation. Drawing on historical examples and empirical evidence about resurgence, this new report demonstrates why it is crucial for U.S. policymakers to invest in the Global Fund.
Previously recommended treatment regimens for drug-resistant tuberculosis (DR-TB) used by most countries had a high pill burden, long treatment duration (of up to two years), painful daily injections (for up to eight months), severe side effects (due to toxic drugs) and poor treatment outcomes. These suboptimal regimens achieved treatment success rates of only 55% for people with multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) and 34% for people with extensively drug-resistant TB.
The World Health Organization (WHO) issued new MDR/RR-TB treatment guidelines in March 2019. This technical brief provides a summary of the treatment regimens now recommended by WHO, which represent hope for people with DR-TB and their caregivers because they offer better cure rates and fewer side effects using safer all-oral treatment.
Médecins Sans Frontières (MSF) urges countries to make a timely switch to the...
In the era of declining development assistance for health, transitioning externally funded programs to governments becomes a priority for donors. However, the process requires a careful approach not only to preserve the public health gains that have already been achieved but also to expand on them. In the Eastern Europe and Central Asia region, countries are expected to graduate from support from the Global Fund to Fight AIDS, Tuberculosis and Malaria in or before 2025. We aim to describe transition risks and identify possible means to address them.
Publisher: Journal of the American Medical Association
In 2015, member states of the United Nations adopted the ambitious Sustainable Development Goals (SDGs), which included 17 global goals that targeted economic and social development.1 Goal 3, “to ensure healthy lives and promote well-being for all at all ages,” targets specifically marked progress in universal health coverage; improved access to safe, effective, and affordable medicines; and the end of the HIV, malaria, and tuberculosis epidemics by 2030.
This study aims to analyze different patterns and gaps of care along the care cascade across countries and to develop a model to examine the relationship between performance of tuberculosis programmes in high and low burden countries along the tuberculosis care cascade and tuberculosis disease burden.